Israeli’s anti-virus spray to begin UK clinical trials this week
search

The latest Jewish News

Read this week’s digital edition

Click Here

Israeli’s anti-virus spray to begin UK clinical trials this week

SaNOtize Nitric Oxide Nasal Spray, developed by a firm co-founded by Israeli Gilly Regev, is believed to kill up to 99.9% of the coronavirus that causes Covid-19.

The first UK clinical trials of a nasal spray developed by a company co-founded by an Israeli that kills 99.9% of the coronavirus that causes Covid-19, begins this week.

The SaNOtize Nitric Oxide Nasal Spray (NONS) is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.

The treatment, developed by SaNOtize Research and Development Corp. based in Vancouver, Canada, co-founded by Israeli Gilly Regev, proved 99.9% effective in killing the coronavirus in independent lab tests at Utah State University’s Antiviral Research Institute.

Additional studies in rodents with COVID-19 infection showed over 95% reduction within the first day after infection. It is currently undergoing Phase II clinical trials throughout Canada approved by Health Canada, and in other countries.

The SaNOtize treatment is based on nitric oxide, a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes Covid-19. The treatment can be delivered by nasal spray, throat gargle or nasal lavage.

Lab tests on the SaNOtize treatment at Utah State University’s Antiviral Research Institute confirmed that the company’s Nitric Oxide Releasing Solution inactivated more than 99.9% of SARs-CoV-2, the virus that causes Covid-19, within two minutes.

Rodent studies performed at Colorado State University showed an average of over 95% reduction in SARS-CoV-2 viral load tested on the day following infection with half the rodents having no detectable virus at all. This was following inoculation with the virus and two treatments of SaNOtize’s nasal spray.

“Any intervention for treating coronavirus – the virus responsible for Covid-19 – is to be welcomed. The fact that a relatively easy and simple nasal spray could be an effective treatment is welcome news and offers a significant advance in our therapeutic armoury against this devastating disease. Ashford and St Peters Hospitals NHS Foundation Trust is proud to be at the forefront of trialling this intervention,” said Pankaj Sharma MD PhD FRCP, Professor of Neurology and Director of the Institute of Cardiovascular Research at Royal Holloway, University of London.

Rob Wilson, a former British government minister who represents SaNOtize in the UK and EU, is overseeing the trial.

“If, as we expect, the current Phase II results in Canada confirm the very encouraging results received from the Antiviral Research Institute and ongoing studies at Colorado State University SaNOtize will be seeking emergency approval in Canada to proceed directly to Phase IV introduction of the product to the market as part of the continuing global fight against this deadly pandemic,” said Wilson.

Support your Jewish community. Support your Jewish News

Thank you for helping to make Jewish News the leading source of news and opinion for the UK Jewish community. Today we're asking for your invaluable help to continue putting our community first in everything we do.

Unlike other Jewish media, we do not charge for content. That won’t change. Because we are free, we rely on advertising to cover our costs. This vital lifeline, which has dropped in recent years, has fallen further due to coronavirus.

For as little as £5 a month you can help sustain the vital work we do in celebrating and standing up for Jewish life in Britain.

Jewish News holds our community together and keeps us connected. Like a synagogue, it’s where people turn to feel part of something bigger. It also proudly shows the rest of Britain the vibrancy and rich culture of modern Jewish life.

You can make a quick and easy one-off or monthly contribution of £5, £10, £20 or any other sum you’re comfortable with.

100% of your donation will help us continue celebrating our community, in all its dynamic diversity...

Engaging

Being a community platform means so much more than producing a newspaper and website. One of our proudest roles is media partnering with our invaluable charities to amplify the outstanding work they do to help us all.

Celebrating

There’s no shortage of oys in the world but Jewish News takes every opportunity to celebrate the joys too, through projects like Night of Heroes, 40 Under 40 and other compelling countdowns that make the community kvell with pride.

Pioneering

In the first collaboration between media outlets from different faiths, Jewish News worked with British Muslim TV and Church Times to produce a list of young activists leading the way on interfaith understanding.

Campaigning

Royal Mail issued a stamp honouring Holocaust hero Sir Nicholas Winton after a Jewish News campaign attracted more than 100,000 backers. Jewish News also produces special editions of the paper highlighting pressing issues including mental health and Holocaust remembrance.

Easy access

In an age when news is readily accessible, Jewish News provides high-quality content free online and offline, removing any financial barriers to connecting people.

Voice of our community to wider society

The Jewish News team regularly appears on TV, radio and on the pages of the national press to comment on stories about the Jewish community. Easy access to the paper on the streets of London also means Jewish News provides an invaluable window into the community for the country at large.

We hope you agree all this is worth preserving.

read more:
comments